Literature DB >> 19406190

Reduction in the incidence of invasive pneumococcal disease after general vaccination with 7-valent pneumococcal conjugate vaccine in Germany.

Simon Rückinger1, Mark van der Linden, Ralf René Reinert, Rüdiger von Kries, Florian Burckhardt, Anette Siedler.   

Abstract

General vaccination with the 7-valent pneumococcal conjugate vaccine was recommended in Germany in July 2006 for all children <2 years. The proportion of reported invasive pneumococcal disease (IPD) caused by vaccine serotypes before vaccine introduction was considerably lower than in the US. We report data from nationwide surveillance of IPD in children with two reporting sources, pediatric hospitals and microbiological laboratories in Germany. Incidence rates with regard to age groups and pneumococcal serotypes are based on capture recapture estimates combining the two reporting sources. Between July 1, 1997 and June 30, 2003, 2680 cases (an average 447 yearly cases) of IPD were observed in children <16 years in Germany compared to 223 cases between July 1, 2007 and June 30, 2008. A significant reduction in overall incidence (4/100,000-3.2/100,000) was attributed to significant reductions in children younger than 2 years (20.0/100,000-11.0/100,000). While the incidence of all serotypes included in the vaccine was reduced in the age group <2 years, the incidence of non-vaccine serotypes remained stable. These data show a first success of the pneumococcal vaccination program in Germany. Further changes in incidence and serotype distribution of IPD are subject to future surveillance.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19406190     DOI: 10.1016/j.vaccine.2009.04.057

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  34 in total

Review 1.  Vaccination recommendations for Germany.

Authors:  Miriam Wiese-Posselt; Christine Tertilt; Fred Zepp
Journal:  Dtsch Arztebl Int       Date:  2011-11-04       Impact factor: 5.594

Review 2.  Serotype replacement in disease after pneumococcal vaccination.

Authors:  Daniel M Weinberger; Richard Malley; Marc Lipsitch
Journal:  Lancet       Date:  2011-04-12       Impact factor: 79.321

3.  Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany.

Authors:  Alexander Kuhlmann; J-Matthias Graf von der Schulenburg
Journal:  Eur J Health Econ       Date:  2016-02-23

4.  Epidemiologic and clinical implications of second-generation pneumococcal conjugate vaccines.

Authors:  Carmen Muñoz-Almagro; Adoracion Navarro-Torne; Roman Pallares
Journal:  Curr Infect Dis Rep       Date:  2013-04       Impact factor: 3.725

5.  Outpatient Antibiotic Prescription.

Authors:  Jörg Bätzing-Feigenbaum; Maike Schulz; Mandy Schulz; Ramona Hering; Winfried V Kern
Journal:  Dtsch Arztebl Int       Date:  2016-07-01       Impact factor: 5.594

Review 6.  Cost effectiveness of the new pneumococcal vaccines: a systematic review of European studies.

Authors:  Katelijne van de Vooren; Silvy Duranti; Alessandro Curto; Livio Garattini
Journal:  Pharmacoeconomics       Date:  2014-01       Impact factor: 4.981

7.  Pneumococcal vaccination rates in adults in Germany: an analysis of statutory health insurance data on more than 850,000 individuals.

Authors:  Ulrike Theidel; Alexander Kuhlmann; Anja Braem
Journal:  Dtsch Arztebl Int       Date:  2013-11-01       Impact factor: 5.594

8.  Effects of pneumococcal conjugate vaccine 2 years after its introduction, the Netherlands.

Authors:  Gerwin D Rodenburg; Sabine C de Greeff; Angelique G C S Jansen; Hester E de Melker; Leo M Schouls; Eelko Hak; Lodewijk Spanjaard; Elisabeth A M Sanders; Arie van der Ende
Journal:  Emerg Infect Dis       Date:  2010-05       Impact factor: 6.883

9.  Temporal Variations among Invasive Pneumococcal Disease Serotypes in Children and Adults in Germany (1992-2008).

Authors:  Matthias Imöhl; Ralf René Reinert; Mark van der Linden
Journal:  Int J Microbiol       Date:  2010-06-30

10.  Effect of heptavalent pneumococcal conjugate vaccination on invasive pneumococcal disease in preterm born infants.

Authors:  Simon Rückinger; Mark van der Linden; Rüdiger von Kries
Journal:  BMC Infect Dis       Date:  2010-01-19       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.